Thomas H Beckham1, Dana L Casey1, Michael P LaQuaglia2, Brian H Kushner3, Shakeel Modak3, Suzanne L Wolden4. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Pediatric Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: woldens@mskcc.org.
Abstract
PURPOSE: To analyze the renal function outcomes in patients undergoing radiation therapy for neuroblastoma. METHODS AND MATERIALS: The clinical metrics of renal function were analyzed in patients undergoing radiation therapy for high-risk neuroblastoma from 2000 to 2015. The blood urea nitrogen (BUN) and creatinine values before radiation therapy were compared with last available follow-up values and analyzed with the clinical circumstances, including follow-up length, age at primary irradiation, nephrectomy, and radiation technique. The creatinine clearance was estimated using the Shull method. RESULTS: With a median follow-up period of 3.5 years, none of the 266 patients studied developed a chronic renal insufficiency. For all patients, the creatinine level increased from 0.44 to 0.51 mg/dL and the BUN increased from 10.53 to 15.52 mg/dL. Three patients required antihypertensive medication. The patients who underwent intensity modulated radiation therapy did not experience increased creatinine levels during the follow-up period; however, they had a reduced median follow-up length compared with patients treated with anteroposterior/posteroanterior beams (4.7 vs 3.3 years). A longer follow-up length was associated with an increased creatinine level. The preradiation therapy creatinine level increased with patient age, similar to that of the last follow-up creatinine level, suggesting that the changes in creatinine could likely be explained by physiologic increases associated with aging rather than radiation-induced renal damage. The creatinine clearance did not decrease in any circumstance. CONCLUSIONS: The present cohort had excellent renal outcomes after radiation therapy for neuroblastoma. No patient developed chronic renal insufficiency, and the small increases in BUN and creatinine we observed correlated, as expected, with increases in patient age. The results of the present study revealed a possible advantage for intensity modulated radiation therapy in preserving renal function; however, the follow-up length is a recognized confounding variable. The kidneys are vital structures to consider when planning radiation therapy for neuroblastoma patients, and we have found encouraging evidence that modern techniques to spare them in the setting of multiple treatment-related insults have been successful.
PURPOSE: To analyze the renal function outcomes in patients undergoing radiation therapy for neuroblastoma. METHODS AND MATERIALS: The clinical metrics of renal function were analyzed in patients undergoing radiation therapy for high-risk neuroblastoma from 2000 to 2015. The blood ureanitrogen (BUN) and creatinine values before radiation therapy were compared with last available follow-up values and analyzed with the clinical circumstances, including follow-up length, age at primary irradiation, nephrectomy, and radiation technique. The creatinine clearance was estimated using the Shull method. RESULTS: With a median follow-up period of 3.5 years, none of the 266 patients studied developed a chronic renal insufficiency. For all patients, the creatinine level increased from 0.44 to 0.51 mg/dL and the BUN increased from 10.53 to 15.52 mg/dL. Three patients required antihypertensive medication. The patients who underwent intensity modulated radiation therapy did not experience increased creatinine levels during the follow-up period; however, they had a reduced median follow-up length compared with patients treated with anteroposterior/posteroanterior beams (4.7 vs 3.3 years). A longer follow-up length was associated with an increased creatinine level. The preradiation therapy creatinine level increased with patient age, similar to that of the last follow-up creatinine level, suggesting that the changes in creatinine could likely be explained by physiologic increases associated with aging rather than radiation-induced renal damage. The creatinine clearance did not decrease in any circumstance. CONCLUSIONS: The present cohort had excellent renal outcomes after radiation therapy for neuroblastoma. No patient developed chronic renal insufficiency, and the small increases in BUN and creatinine we observed correlated, as expected, with increases in patient age. The results of the present study revealed a possible advantage for intensity modulated radiation therapy in preserving renal function; however, the follow-up length is a recognized confounding variable. The kidneys are vital structures to consider when planning radiation therapy for neuroblastomapatients, and we have found encouraging evidence that modern techniques to spare them in the setting of multiple treatment-related insults have been successful.
Authors: Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-27 Impact factor: 7.038
Authors: Ilona A Dekkers; Karin Blijdorp; Karlien Cransberg; Saskia M Pluijm; Rob Pieters; Sebastian J Neggers; Marry M van den Heuvel-Eibrink Journal: Clin J Am Soc Nephrol Date: 2013-02-14 Impact factor: 8.237
Authors: Sebastiaan L Knijnenburg; Renée L Mulder; Antoinette Y N Schouten-Van Meeteren; Arend Bökenkamp; Hester Blufpand; Eline van Dulmen-den Broeder; Margreet A Veening; Leontien C M Kremer; Monique W M Jaspers Journal: Cochrane Database Syst Rev Date: 2013-10-08
Authors: Nai-Kong V Cheung; Irene Y Cheung; Brian H Kushner; Irina Ostrovnaya; Elizabeth Chamberlain; Kim Kramer; Shakeel Modak Journal: J Clin Oncol Date: 2012-08-06 Impact factor: 44.544
Authors: Brian H Kushner; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Kim Kramer; Nai-Kong V Cheung Journal: Cancer Date: 2013-04-30 Impact factor: 6.860
Authors: Alexander F Bagley; David R Grosshans; Nancy V Philip; Jennifer Foster; Mary Frances McAleer; Susan L McGovern; Yasmin Lassen-Ramshad; Anita Mahajan; Arnold C Paulino Journal: Pediatr Blood Cancer Date: 2019-05-02 Impact factor: 3.167
Authors: John T Lucas; M Beth McCarville; David A Cooper; Mikhail Doubrovin; Daniel Wakefield; Teresa Santiago; Yimei Li; Xingyu Li; Matthew Krasin; Victor Santana; Wayne Furman; Andrew M Davidoff Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-26 Impact factor: 7.038